Effect of allopregnanolone on stress-induced craving

项目总结/摘要 长期以来，压力系统失调在酒精使用病因学中的重要性一直受到关注。 建立，并寻找参与这一过程的调节剂和机制， 一个持续的研究目标。神经类固醇被认为是调节压力的中心 反应和最近的证据表明，一种新的神经类固醇，allopregnanolone介导酒精 强化、容忍、依赖和退缩。我们建议解释的作用，和 别孕烯醇酮对酒精影响的机制，通过确定是否静脉输注 别孕烯醇酮减弱压力诱导的酒精渴望，压力诱导的焦虑，和主观 使用实验室范例的酒精的刺激/镇静作用。的次要目的 该项目是表征别孕烯醇酮的行为效应。这是一个双盲， 在非寻求治疗的AUD个体中进行的安慰剂对照、受试者间研究。所有 参与者将连续输注（160分钟）单剂量别孕醇酮 （目标剂量100 nM）或安慰剂。在单个试验日，输注60分钟后-当ALLO水平 稳定-压力和中性线索组成的个性化5分钟脚本将在 随机顺序压力诱发的渴望和压力诱发的焦虑的测量将在 提示（前），提示后立即（后）和提示后10分钟（恢复）。期间 前60分钟的输注测量将评估情绪、认知和运动协调 管理。所有参与者还将接受静脉注射酒精， 钳夹程序，目标是40mg%（40 mg/dL）。将在脚本演示后给予酒精（20分钟至目标时间 再夹持30分钟）。 该项目的主要目的是检查别孕烯醇酮作为一种 酒精使用障碍的可能治疗方法。我们希望确定别孕烯醇酮是否上级于 安慰剂减少酒精渴望，焦虑和主观刺激/镇静作用 实验室里的酒精这项研究是第一次检查的治疗潜力， 别孕烯醇酮及其作为酒精使用障碍的可能治疗的作用机制。

Project Summary/Abstract The importance of the stress-system dysregulation in the etiology of alcohol use has long been established, and the search for modulators and mechanisms that are involved in this process has been an ongoing goal of research. Neurosteroids are considered central in the regulation of the stress response and recent evidence suggests that a new neurosteroid, allopregnanolone mediates alcohol reinforcement, tolerance, dependence and withdrawal. We propose to explicate the role, and the mechanisms of allopregnanolone on alcohol effects by determining whether intravenous infusion of allopregnanolone attenuates stress-induced alcohol craving, stress-induced anxiety, and subjective stimulant/sedative effects of alcohol using a laboratory paradigm. The secondary objective of this project is to characterize the behavioral effects of allopregnanolone. This is a double-blind, placebo-controlled, between-subjects study in non-treatment seeking individuals with AUD. All participants will receive a continuous infusion (160 minutes) of a single dose of allopregnanolone (targeted dose 100 nM) or placebo. On a single test day, after 60 min of infusion - when ALLO levels stabilize - stress and neutral cues consisting of personalized 5 minutes scripts will be presented in random order. Measures of stress-induced craving and stress-induced anxiety will be collected before the cue (pre), immediately following the cue (post) and 10 min after (recovery) the cue. During the first 60 min. of infusion measures evaluating mood, cognition and motor coordination will be administered. All participants will also receive alcohol administered intravenously using a clamp procedure, targeting a breath alcohol concentration (BrAc) of 40mg% (40 mg/dL). Alcohol will be administered following script presentation (20 min to target and clamped for additional 30min). The main aim of this project is to examine the safety and efficacy of allopregnanolone as a possible treatment for alcohol use disorders. We wish to determine if allopregnanolone is superior to placebo in reducing alcohol craving, anxiety and subjective stimulant/sedative effects of alcohol in the laboratory. This study is the first to examine the therapeutic potential of allopregnanolone and its mechanism of action as a possible treatment for alcohol use disorders.